Bae Hayeon, Ji Hyunsub, Konstantinov Konstantin, Sluyter Ronald, Ariga Katsuhiko, Kim Yong Ho, Kim Jung Ho
Institute for Superconducting & Electronic Materials (ISEM), Faculty of Engineering and Information Sciences, University of Wollongong Innovation Campus, Squires Way, North Wollongong, NSW, 2500, Australia.
Department of Nano Science and Technology, SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University (SKKU), 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, 16419, Republic of Korea.
Adv Mater. 2025 Oct;37(42):e10239. doi: 10.1002/adma.202510239. Epub 2025 Aug 7.
The development of data-driven and targeted drug delivery systems is essential for advancing precision therapeutics. Despite substantial progress in nanocarrier development, conventional platforms continue to face major challenges in clinical translation due to biological complexity, off-target accumulation, and limited adaptability to dynamic physiological environments. The integration of nanoarchitectonics and artificial intelligence (AI) offers an advanced strategy for engineering delivery systems that are structurally programmable, stimuli-responsive, and autonomously optimized. Nanoarchitectonics enables the construction of hierarchical nanostructures with precise spatial and temporal control, while AI facilitates modeling, prediction, and iterative optimization throughout the development pipeline. In this perspective, an AI-driven nanoarchitectonics framework is introduced for targeted drug delivery, structured around three key phases: 1) molecular target identification through bioinformatic profiling, 2) machine learning (ML)-guided surface engineering to enhance targeting specificity, and 3) in silico modeling of delivery dynamics and systemic distribution. Drawing on recent advances and representative case studies, how AI tools are illustrated, from generative design algorithms to predictive pharmacokinetic models, are transforming the field from empirical formulation toward mechanism-informed and AI-driven intelligent design. By highlighting current limitations and outlining future directions for the integration of AI and nanoarchitectonics, are concluded with a focus on enabling clinically translatable nanomedicine platforms.
数据驱动和靶向给药系统的发展对于推进精准治疗至关重要。尽管纳米载体的开发取得了重大进展,但传统平台由于生物复杂性、脱靶积累以及对动态生理环境的适应性有限,在临床转化方面仍面临重大挑战。纳米结构技术与人工智能(AI)的整合为构建结构可编程、刺激响应性和自主优化的给药系统提供了一种先进策略。纳米结构技术能够在精确的时空控制下构建分级纳米结构,而人工智能则有助于在整个开发过程中进行建模、预测和迭代优化。从这个角度出发,本文介绍了一种用于靶向给药的人工智能驱动的纳米结构技术框架,该框架围绕三个关键阶段构建:1)通过生物信息学分析识别分子靶点;2)机器学习(ML)指导的表面工程,以提高靶向特异性;3)给药动力学和全身分布的计算机模拟。借鉴近期的进展和代表性案例研究,展示了人工智能工具,从生成设计算法到预测性药代动力学模型,如何将该领域从经验性配方转变为基于机制和人工智能驱动的智能设计。通过强调当前的局限性并概述人工智能与纳米结构技术整合的未来方向,本文最后聚焦于实现可临床转化的纳米医学平台。